Bladder cancer after managing upper urinary tract transitional cell carcinoma: risk factors and survival

Int Urol Nephrol. 2011 Sep;43(3):729-35. doi: 10.1007/s11255-011-9902-4. Epub 2011 Feb 26.

Abstract

Objective: To identify independent risk factors for the development of bladder cancer after surgical management of upper urinary tract transitional cell carcinoma (UUT-TCC).

Patients and methods: Between January 1999 and December 2008, 154 patients were treated surgically for UUT-TCC at the Clinic of Urology, Clinical Center of Serbia. Patients with a previous history of bladder cancer and patients with concomitant bladder cancer were excluded from the study. In all, 92 patients were then available for evaluation. The median follow-up after surgery was 39.5 months. Univariate and multivariate analyses using the logistic regression model were performed. The intravesical disease-free rate and survival were calculated using the Kaplan-Meier method, and the log-rank test was used to determine statistical differences.

Results and limitations: In this study, 21.7% patients treated for UUT-TCC developed subsequent bladder tumors. Tumor multifocality was the only independent predictor associated with the development of subsequent bladder cancer (P = 0.028, RR = 3.52). Intravesical recurrence-free survival rates for these 92 patients at 1, 3, 5, and 7 years were 85.8, 80, 79.3, and 78.3%, respectively. Patients with tumors extending to multiple sites were significantly more likely to present subsequent intravesical recurrence (P = 0.006). The development of bladder cancer had no significant effect on the survival of patients who underwent surgical treatment of UUT-TCC, compared to patients without bladder cancer development (P = 0.660). Neither did the type of surgery mode affect patient survival (P = 0.245). This study is limited by biases associated with its retrospective design.

Conclusion: The multiplicity of the UUT-TCC is an independent risk factor for the occurrence of bladder cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Transitional Cell / drug therapy
  • Carcinoma, Transitional Cell / pathology*
  • Carcinoma, Transitional Cell / surgery
  • Chemotherapy, Adjuvant
  • Chi-Square Distribution
  • Disease-Free Survival
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Kidney Neoplasms / drug therapy
  • Kidney Neoplasms / pathology*
  • Kidney Neoplasms / surgery
  • Logistic Models
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / diagnosis*
  • Neoplasms, Multiple Primary / pathology*
  • Neoplasms, Multiple Primary / surgery
  • Retrospective Studies
  • Risk Factors
  • Serbia
  • Ureteral Neoplasms / drug therapy
  • Ureteral Neoplasms / pathology*
  • Ureteral Neoplasms / surgery
  • Urinary Bladder Neoplasms / diagnosis*

Substances

  • Antineoplastic Agents